PlainPharmaWatch

CMS Open Payments · Program Year 2024

Madrigal Pharmaceuticals

Madrigal Pharmaceuticals reported $13,990,298.03 across General Payments, Research, and Ownership to 19,606 physicians and teaching hospitals across 20,808 transactions.

See the rankings → How this is sourced
$14.0M
All-tracks total
20,808
Transactions
19,606
Recipients
#133
of 1,925 companies

Madrigal Pharmaceuticals reported $13,990,298.03 across all CMS Open Payments tracks (General + Research + Ownership) to 19,606 physicians and teaching hospitals in Program Year 2024 - ranking #133 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $4,487,923.64, averaging $713.57 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer madrigal-pharmaceuticals Madrigal Pharmaceuticals

$14.0M · #133/1,925 · 0.1% industry · PY2024

  • TOT $14.0M
  • RANK #133
  • SHARE 0.1%
  • TXN 20,808
  • RCP 19,606
  • CAT 8
  • GEN $4.5M
  • TOP1 2.4%
  • PY 2024

Volume peers

Nearest volume peer: Argenx US, Inc. ($14.1M)

Argenx US, Inc.$14.1MMadrigal Pharmaceuticals (th…$14.0MAtricure, Inc.$13.7MLazurite Inc.$13.6MCentinel Spine, LLC$13.6M
All-tracks payment totals near Madrigal Pharmaceuticals (CMS Open Payments PY2024)

Madrigal Pharmaceuticals sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

What the Data Shows for Madrigal Pharmaceuticals

In Program Year 2024, Madrigal Pharmaceuticals reported $13,990,298.03 in payments to 19,606 physicians and teaching hospitals across 20,808 individual transactions, an average of $672.35 per transaction and $713.57 per recipient. That total places Madrigal Pharmaceuticals at rank #133 out of 1,925 companies in the CMS Open Payments database, representing 0.1% of all industry payments reported nationwide for the year.

Of the 8 general-payment categories charted below, "Compensation for Services Other Than Consulting" is the largest at $3.0M across 1,071 transactions, 67.2% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Across 8 types of general payments, Madrigal Pharmaceuticals's largest category was "Compensation for Services Other Than Consulting" at $3.0M - 67.2% of General Payments.

Madrigal Pharmaceuticals reports 8 general-payment categories - the top three are Compensation for Services Other Than Consulting (67.2%), Food and Beverage (17.2%), and Travel and Lodging (8.2%). The remaining 5 categories make up 7.4% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.

Category breadth matters here: Madrigal Pharmaceuticals files across 8 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.

How Madrigal Pharmaceuticals divides its payments

Ranked by total dollars reported per category

1. Compensation for Services…$3.0M2. Food and Beverage$774.1K3. Travel and Lodging$367.2K4. Honoraria$238.1K5. Consulting Fee$41.2K6. Space Rental or Facility …$40.8K7. Education$6.0K8. Grant$5.0K
Payment Type Amount Transactions
Compensation for Services Other Than Consulting $3.0M 1,071
Food and Beverage $774.1K 17,111
Travel and Lodging $367.2K 1,140
Honoraria $238.1K 68
Consulting Fee $41.2K 66
Space Rental or Facility Fees $40.8K 7
Education $6.0K 141
Grant $5.0K 2

Recipient Concentration in General Payments

The five largest recipient relationships account for $381,665.20 (8.5%) of $4,487,923.64 in this company's General Payments records across 8,963 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Madrigal Pharmaceuticals

The five named recipients with the highest reported General Payments from this company

Santiago Munoz$108.3KZahid Vahora$86.2KNaim Alkhouri$80.3KJulio Gutierrez$53.7KNadege Gunn$53.2K
  1. 1

    Santiago Munoz

    $108,335.69 across 94 reported transactions

  2. 2

    Zahid Vahora

    $86,245.77 across 61 reported transactions

  3. 3

    Naim Alkhouri

    $80,263.56 across 53 reported transactions

  4. 4

    Julio Gutierrez

    $53,664.69 across 45 reported transactions

  5. 5

    Nadege Gunn

    $53,155.49 across 54 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Madrigal Pharmaceuticals's, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Madrigal Pharmaceuticals.

Virtus Pharmaceuticals LLC

HHI 50

Mylan Specialty L.P.

HHI 51

Electronic Waveform Lab, Inc.

HHI 47

Avvisto Therapeutics, LLC

HHI 47

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Madrigal Pharmaceuticals.

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Madrigal Pharmaceuticals's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.